The significance of N6-methyladenosine-modified non-coding RNAs in different disorders

N6-methyladenosine (m6A) is the most widespread endogenous modification affecting the expression of eukaryotic mRNA transcripts. Recent studies have shown that the m6A marks within non-coding RNAs can affect their functions and expression in a manner similar to that of mRNA-coding genes. Since non-coding RNAs are involved in the pathophysiology of several disorders, identification of the role of m6A marks in the regulation of expression of non-coding RNAs can open a new era for identifying underlying mechanisms of several disorders and designing novel therapeutic modalities for a variety of disorders, particularly cancers. Moreover, a number of non-coding RNAs can affect m6A levels. In the current review, we discuss the impacts of m6A marks on the expression of non-coding RNAs in the context of different disorders, such as bone, gastrointestinal, neurologic, renal, pulmonary, hepatic and other disorders.

Automated summary

N6-methyladenosine (m6A) is a common endogenous modification that affects the expression of eukaryotic mRNA transcripts. Recent studies have shown that m6A marks in non-coding RNAs can also impact their functions and expression, similar to mRNA-coding genes. Understanding the role of m6A marks in the regulation of non-coding RNA expression can provide insights into the mechanisms of various disorders and potentially lead to new therapeutic approaches, especially for cancers. Additionally, non-coding RNAs themselves can influence m6A levels.